i Summary: Immunoluminometric assays were developed for apolipoproteins A-I, B, C-II (äs the apolipoprotein C-II: apolipoprotein B complex), apolipoprotein(a) and lipoprotein(a). The assays were evaluated clinically and methodologically. The results for apolipoprotein A-I, apolipoprotein B and lipoprotein(a) were compared with those obtained by turbidimetric assays. No comparison was possible for apolipoprotein C-II.
Introduction
has improved the armamentarium available for the surveillance, prevention and combatting of atherosclerosis The introduction of apolipoprotein determination in ad-and coronary heart disease (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Lipoprotein(a) has dition to the "classical" lipid metabolism quantities, such been shown to be an important independent marker for äs triacylglycerols and different cholesterol fractions, atherosclerosis; itisclosely related to plasminogen (11) (12) (13) (14) (15) , thus providing a possible link between lipid metabolism and haemostaseology.
Most methods for determination of apolipoproteins are based on turbidimetry or nephelometry, äs the relatively high concentrations in blood do not necessarily demand methods with a very low detection limit. The determination of lipoprotein(a) using turbidimetry or nephelometry has proved problematic with regard to sample type (serum or plasma) and reproducibility.
Immunometric technology allows the specific determination of defined apolipoproteins, äs well äs enabling the determination of particles containing different apolipoproteins. The main disadvantage of the method is the dilution Step often needed prior to assay. This is compensated by the application of the method to long series, for example in screening procedures. This technology provides a reliable and specific quantification of analytes that are present in blood in low concentrations, in the present case apolipoprotein C-II complexed with apolipoproteinN.B.
All assays are based on commercially availäble reagents and can be set up in any laboratory with suitable measuring equipment. Since the methods use biotinylated antibodies and labelled streptavidin, they can also be adapted for radioisotopic, enzyme or time-resolved fluorescence markers.
Materials and Methods

Materials
Antibodies were purchased from the following sources:
Dako, Hamburg, Germany, Immuno, Heidelberg, Germany, Atlantic Antibodies (ATAB) (Serva), Heidelberg, Germany, Boehringer-Mannheim, Mannheim, Germany, Calbiochem-Novabiochem, Bad Soden, Germany.
The combination and source of the antibodies for each assay is given below.
Standard and control materials were obtained from BoehringerMannheim, Immuno, Behringwerke, Marburg a.d.L., Germany, Röche Diagnostics, Grenzach-Wyhlen, Germany and Dako.
Amidocaproylbiotin N-hydroxysuccinimide was purchased from Sigma, Deisenhofen, Germany. Streptavidin was obtained from Biomol, Hamburg, Germany. 9-[N-(4-aminobutyl)-N-ethyl] aminobenzo(f)phthalazine 1,4 (2H,3H) dione (ABEN) was synthesised in the Institute for Biochemical Endocrinology of the Medical University of Lübeck.
Polystyrene balls (6.4 mm diameter) were obtained from Spherotech Kugeln GmbH, Fulda, Germany.
Buffer substances were purchased from Merck, Darmstadt, Germa o ny or from Sigma.
Methods
The biotinylation of antibodies and labelling of streptavidin with ABEN was carried out äs previously described (16, 17) . Incubate for 30 min and wash with 3 X 5 ml demineralised water. *) Transfer ball to measuring cuvette, add 300 catalase, load luminometer and initiate reaction with 300 alkaline peroxide, integrating the light signal over 4 seconds. *) Füll details of the reagents for luminometry have beeri published in detail elsewhere -see I.e. (16, 17) .
The assay scheme was the same for all analytes and is shown in table l. Comparative methods were carried out on the Cobas MIRA (Röche Diagnostics) using turbidimetric methodology. The Standards and antiserum used were from imrnuno for lipoprotein(a), and from Röche for apolipoprotein A-t and B for turbidimetry. The Standards for all five immunoluminornetric assays were all from Immuno.
The antibody combinations for the immunoluminornetric assays developed were äs follows: The best results were obtained with the combination of the antibodies shown above. The sample was assayed at dilutions of l : 500, l : 1000 and l : 2000. the Standard curve covered the concentration ränge 0.125-2 mg/1 (effective ränge up to 4 g/l). The Standard had been calibrated against the proposed WHO Standard (18) (19) (20) and was supplied by immuno.
Apolipoprotein B
The combination of antibodies was best äs shown above. The Standard had been calibrated against the proposed WHO Standard and eovered the ränge 0.125-4 mg/1 (effective ränge up to 4 g/l). Samples were diluted l : 250, : 500 and l : 1000 before being assayed. The same Standard was used'as for apolipoprotein A-l. »»
Apolipoprotein C-U: Apolipoprotein B
Samples were assayed neat using a serum calibrator for apolipoprotein C-II supplied by Immuno. The Standard curve covered the ränge 3.5-105 mg/1.
Lipoprotein(a)
The Standard used was for apolipoprotein(a) below, the specificity of the assay being determined by the use of anti-lipoprotein(a) on the solid phase and anti-apolipoprotein B äs Sandwich partner. Samples were dituted 1:10 and l : 50 before assay.
Apolipoprotein (a)
Samples were assayed using a l : 10 and l : 50 dilution using a Standard curve which covered the ränge 0-80 mg/l (effective ränge 0-4000 mg/1). The Standard material was from Immuno. The antibody combination shown above was the only one in which samples diluted linearly. The hope that firee apolipoprotein(a) could be estimated from the diflference between apolipoprotein(a) and lipoprotein(a) was not realisable due to the unknown airiount of free apolipoprotein(a) in the Standard used (Information from Immuno).
Statistics
Non-parametric statistics were used throughout and correlations were performed with the Spearman rank correlation method. The median was used äs the marker of central tendency and relevant percentiles for the ränge, äs the distribution of apolipoprotein(a) and lipoprotein(a) concentrations was highly skewed (mean: median > 2.5).
Results and Discussion
Tables 2a-2b show quality assessment data for all five assays. The results of geometric dilution of selected samples are given in tables 3a and 3b.
The results show the large measuring ränge of the immunoluminometric assays, which allows very low concentrations of apolipoprotein C-II: apolipoprotein B comp lexes to be measured. Those patients presenting with metabolic disturbances, either with very low levels of this analyte (5) or with deficient lipoprotein lipase can be diagnosed reliäbly.
The precision of the assays is acceptable, älthough the accuracy, äs far äs this can be measured, must be questioned for the turbidimetric assay, especially in lipaemic sera. The relatively high coefficients of Variation for the immunoluminometric assays for apolipoprotein % A-I and apolipoprotein B are due to the large dilution factors coupled with the small sample volüme. No attempt was made to determine a reference ränge for healthy adults for any of the apolipoproteins, since there is an ongoing debate äs to whether values for single apolipoproteins have any significance. From the correlation studies it can be seen that the assays presented here do not give very different results from the established routine serum nephelömetric assay for lipoprotein(a). The results for apolipoproteins A-I and B were not äs good.
The assays for apolipoproteins A-I, B, and C-II:B show a linear dilution pattern, showing that Standards and samples behave in a similar way. Serum matrix effects were not apparent, but this may be due to the low concentrations of serum proteins, especially in the assays for apolipoprotein A-I and apolipoprotein B. The results of geometric dilution of selected samples for apolipoprotein(a) and lipoprotein(a) are given in table 3b. Stability studies for lipoprotein(a) and apolipoprotein(a) are shown in figure 2. Figure 3 shows the comparison between serum and EDTA-plasma lipoprotein(a) in 20 patients, with concentrations throughout the expected measuring ränge. Table 3b shows that not all sera dilute out äs expected, which may reflect the different immunoreactivity of the small and large lipoprotein(a) molecules.
The results show that the immunoluminometric assays have a wide measuring ränge, which allows very low concentrations of lipoprotein(a) and apolipoprotein(a) to be measured.
The precision of the assays is acceptable, älthough the accuracy, äs far äs this can be measured, must be questioned for the nephelömetric assay, especially in lipaemic sera. The nephelömetric method often gave spurious results ranging from "under the detection limit of the assay'' (due to the high extinction of the sample before reaction), to non-linear dilution curves; both effects were observed in lipaemic sera, and were not present in the immunoluminometric assays. The nephelömetric assay was not able to measure lipoprotein(a) in plasma, all values being above 1000 mg/1. These findings point to the necessity of analysing serum when using nephelö-metric methods. Figure 3 shows that the immunoluminometric methods can be applied to serum or plasma.
The stäbility of lipoprotein(a) allows samples to be stored at 4 °C, samples stored in this way usually being stable for several weeks ( fig. 2 ). Commercial control sera could be stored at 4 °C without loss of immunoreactive apolipoprotein(a) or lipoprotein(a). These observations are in accordance with those of Gllleiy et al. The prediluted Standard curve for (apo)lipoprotein(a) (1:10 dilution) in assay buffer is stable at 4 °C for at least 10 days, so that Standards can be prepared once a week. Prediluted sera (1 : 10) can also be stored at 4 °C for at least a week without noticeable changes in the immunoreactivity of (apo)lipoprotein(a). When these Standards or samples were stored at higher dilutions than 1 : 500 there was a loss of immunoreactivity after 7-10 days at 4 °C. No advantage was gained by storing the diluted samples/standards at -20 or -30 °C.
The excellent correlation between the two immunoluminometric assays and the poor correlation between the nephelometric assay and each of the immunoluminometric assays for apolipoprotein(a) and lipoprotein(a) reflects the practical problems of nephelometric measurements. The use of robust immunometric assays with signal detection is to be recommended for the determination of apolipoprotein(a) and lipoprotein(a) in serum. The non-concordance of results for apolipoprotein(a) and lipoprotein(a) is probably not due to free apolipoprotein(a) i. e. the fraction not bound to apolipoprotein B-100.
The different serum concentrations found for apolipoprotein^) and lipoprotein(a) cannot be explained entirely by the presence of free apolipoprotein(a), nor by a cross-reactivity or displacement of apolipoprotein B-100 by apolipoprotein B-48 in the binding to the antiapolipoprotein B on the solid phase. In view of the fact Tab. 3b Geometrie dilutions of selected sera and plasma for (apo)lipoprotein(a). that apolipoprotein B-100 is found in üpoproteiii(a), but not in apolipoprotein(a), and free apolipoprotein(a) may be present in serum in different amoimts, the results should, if anything, be higher for apolipoprotein(a) than for lipoprotein(a). This was not observed (see fig. le ).
The results from the present study agree however with those ofMärz and coworkers, who found a much greater discrepancy between plasma lipoprotein(a) and apolipo·-protein(a) using commercial kits, the slope of the regression line being between 0.34 and 0.54, depending upon the calculation method (14) . As the anti apolipoprotein(a) antisera are both polyclonal, it is not to be expected that they are directed against a single epitope, even when the inanufacturers «täte that they are specific for apolipoprotein(a), antibodies against plasminogen having been removed by immunoadsorption. The antibodies are specific for conformational epitopes, which most probably differ according to the molecular structure of apolipoprotein(a). The differences in the dilution patterns of different sera support this theory. The immunometric assays are better suited to the measurement of lipoprotein(a) and apolipoprotein(a), äs they are designed to measure the molecule specifically and are not influenced by factors such äs lipaemia and the presence of coagulation factors, both of which may influence nephelometric or turbidometric assays. The disadvantage of the immunometric assays is the need for dilution of the sample, although this may dilute out any adverse serum-matrix effects that may be present. The assays are suitable for partial automation and are capable of processing severäl hundred samples per day, a point worth noting when carrying out epidemiological studies or when screening large groups.
The quality assessment is acceptable in terms of interand intra-assay precision. The question of accuracy is still open, due to the absence of an accepted international reference preparation or Standard. The microheterogeneity of lipoprotein(a) and the different genetic variants will make the preparation of a single Standard difficult, especially if the antibodies used only recognise certain genetic variants or conformational epitopes of apolipoprotein(a) (24) . The knowledge of antibody specificity is important in the determination of lipoprotein(a), so that the different forms of the lipoprotein(a) molecule can quantified separately. This would be helpfiil if the different forms of lipoprotein(a) were conclusively shown to have different atherogenic properties.
Further difficulties in assessing the value of studies on lipoprotein(a) lie in the incorrect use of statistics by many groups, where, despite the skewed distribution of values, parametric statistics have been used (25) .
The correlation coefficients, although statistically significant, were not good, especially for apolipoprotein A-I, and many reflect the difference in assay design (competitivc versus Sandwich methodology) äs well äs the Standard used and the effect of the sample material itself. Samples froni dialysis patients were chosen, äs it is known that serum from such patients often presents analytical problems, especially in nephelometric and turbidimetric assays due to the native turbidity of the sample. The Standard from Röche used on the Cobas MIRA gave a non-linear dilution curve for apolipoprotein A-I in the immunoluminometric assay, and values which were up to three times too low, when compared with those from the Standard from Immuno (data not presented here).
The non-standardisation of methods for the apolipoproteins limits the comparability of results obtained by different methods, so that the value of mäny studies must be questioned. Even with the introduction of an international Standard for apolipoprotein A-I and apolipoprotein B (18) (19) (20) it is not to be expected the intermethod comparison will be better. This has been shown repeatedly, especially for proteohormones and polypeptides. In the comparison of 29 methods for apolipoprotein A-I using the proposed new international Standard (20) it was explicitly stated that the values assigned by companies to their secondary Standards only holds for the system used. Any change in the System may give rise to other values (20) . This shows the limits of standardisation by use of a common antigen. Twenty-eight of the 29 methods used in this study to determine apolipoprotein A-I were one-site competitive turbidimetric or nephelometric methods, the remaining assay using radial immunodiffusion. It should be noted, the latter assay gave results which deviated most and had the lowest correlation coefficient
The results for apolipoprotein C-II could not be compared with another method äs none was available. An indirect confirmation that the assay measured in the expected ränge was provided by reference ranges for apolipoprotein C-II (30-80 mg/1) from other sources (26, 27) . In this study, the median conc f entration of 176 dialysis patient samples was 30 mg/1 (ränge 4.1-176 mg/1). The median concentration of 100 non-lipaemic serum samples from healthy adults was 37 mg/1 (ränge 9.6-85 mg/1). There was no sex-linked difference. This represented the amount of apolipoprotein C-II complexed with apolipoprotein B; it was not possible to set up an immunometric method for apolipoprotein C-II alone.
The lower values may be due to the incomplete determination of apolipoprotein , i. e. that not complexed with apolipoprotein B, or to the specificity of the sandwich method or the Standard used. The method and results for apolipoprotein C-II:B complexes have been included to show that it is possible to measure apolipoprotein complexes. Although this assay is of miiiimum routine use, it may be of interest in those centres conceraed with diagnosis of lipoprotein äbnormalities, especially in renal dialysis patients, many of whom are known to have severe lipid disorders. This short communication is intended to demonstrate the use of robust and reliable immunometric methodology in the field of lipid metabolism, especially where large numbers of samples can be analysed economically using commercially available reagents not in kit form. Such assays provide consistent results over a long period, provided sufficient antisera is purchased. This is especially important in long-term epidemiological studies, where methodological Variation must be excluded for an optimal Interpretation of the data obtained.
